Literature DB >> 25108598

Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type.

Etsuko Yamazaki1, Naoto Tomita, Satoshi Koyama, Eriko Ogusa, Yoshimi Ishii, Hiroyuki Takahashi, Kazuho Miyashita, Shiro Matsuura, Takayoshi Tachibana, Hirotaka Takasaki, Sachiya Takemura, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Yoshiaki Ishigatsubo.   

Abstract

The objective of the current study was to assess the prognostic factors in patients with extranodal natural killer (NK)/T cell lymphoma, nasal type (ENKL). We retrospectively analyzed 35 patients who were diagnosed with ENKL between 1998 and 2011. The median patient age was 63 years, and the male/female ratio was 22:13; twenty patients had localized ENKL, and 26 had a good Eastern Cooperative Oncology Group performance status (score 0 or 1). B symptoms were present in 17 patients. Twenty-five patients presented with nasal or paranasal lesions, or both. With a median follow-up duration among patients still alive at their last follow-up of 47 months (range 8-93 months), the 3-year overall survival (OS) rate was 44.5 %. Multivariate analysis revealed that advanced disease stage (P = 0.002), the presence of extranasal disease (P = 0.013), and serum ferritin levels greater than 300 ng/ml (P < 0.001) were significant and independent (negative) prognostic factors. High serum ferritin levels were associated with the presence of B symptoms, elevated lactate dehydrogenase levels, and high soluble interleukin-2 receptor levels, but not with clinical stage. Patients with high ferritin levels had a remarkably low remission rate (23 %) and a short OS time (median: 4 months). Serum ferritin level at the time of diagnosis of ENKL was a useful prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25108598     DOI: 10.1007/s12032-014-0149-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey.

Authors:  L Pagano; A Gallamini; G Trapè; L Fianchi; D Mattei; G Todeschini; A Spadea; S Cinieri; E Iannitto; M Martelli; A Nosari; E Di Bona; M E Tosti; M C Petti; P Falcucci; M Montanaro; A Pulsoni; L M Larocca; G Leone
Journal:  Ann Oncol       Date:  2006-02-23       Impact factor: 32.976

3.  Classification of natural killer (NK) cell and NK-like T-cell malignancies.

Authors:  E S Jaffe
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

4.  Clinical features and prognostic model for extranasal NK/T-cell lymphoma.

Authors:  Jae-Cheol Jo; Dok Hyun Yoon; Shin Kim; Bong-Jae Lee; Yong Ju Jang; Chan-Sik Park; Jooryung Huh; Sang-Wook Lee; Jin-Sook Ryu; Cheolwon Suh
Journal:  Eur J Haematol       Date:  2012-08       Impact factor: 2.997

5.  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.

Authors:  Motoko Yamaguchi; Yok-Lam Kwong; Won Seog Kim; Yoshinobu Maeda; Chizuko Hashimoto; Cheolwon Suh; Koji Izutsu; Fumihiro Ishida; Yasushi Isobe; Eisaburo Sueoka; Junji Suzumiya; Takao Kodama; Hiroshi Kimura; Rie Hyo; Shigeo Nakamura; Kazuo Oshimi; Ritsuro Suzuki
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

6.  Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index.

Authors:  Chor-Sang Chim; Shing-Yan Ma; Wing-Yan Au; Carolyn Choy; Albert K W Lie; Raymond Liang; Chun-Chung Yau; Yok-Lam Kwong
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

Review 7.  Extranodal NK/T-cell lymphoma: diagnosis and treatment cues.

Authors:  Ritsuro Suzuki; Kengo Takeuchi; Koichi Ohshima; Shigeo Nakamura
Journal:  Hematol Oncol       Date:  2008-06       Impact factor: 5.271

8.  Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan: with special reference to T-cell lymphoma.

Authors:  C-Y Chen; M Yao; J-L Tang; W Tsay; C-C Wang; W-C Chou; I-J Su; F-Y Lee; M-C Liu; H-F Tien
Journal:  Ann Oncol       Date:  2004-07       Impact factor: 32.976

9.  Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type.

Authors:  R Suzuki; J Suzumiya; M Yamaguchi; S Nakamura; J Kameoka; H Kojima; M Abe; T Kinoshita; T Yoshino; K Iwatsuki; Y Kagami; T Tsuzuki; M Kurokawa; K Ito; K Kawa; K Oshimi
Journal:  Ann Oncol       Date:  2009-10-22       Impact factor: 32.976

10.  Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin.

Authors:  R Sutherland; D Delia; C Schneider; R Newman; J Kemshead; M Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

View more
  7 in total

Review 1.  Concurrent Epstein-Barr virus associated NK/T cell lymphoma after immunosuppressive therapy for aplastic anemia: report of a case and review of literature.

Authors:  Guangli Yin; Ying Ni; Zhengrui Xiao; Guangsheng He; Kourong Miao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy.

Authors:  Hua Wang; Liang Wang; ZhiJun Wuxiao; HuiQiang Huang; WenQi Jiang; ZhiMing Li; Yue Lu; ZhongJun Xia
Journal:  Onco Targets Ther       Date:  2015-09-14       Impact factor: 4.147

3.  High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma.

Authors:  Jongheon Jung; Hyewon Lee; Ja Yoon Heo; Myung Hee Chang; Eunyoung Lee; Weon Seo Park; Ju-Hyun Park; Hyeon-Seok Eom
Journal:  Sci Rep       Date:  2021-01-29       Impact factor: 4.379

4.  Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer.

Authors:  Sookyung Lee; Anna Song; Wankyu Eo
Journal:  J Cancer       Date:  2016-05-12       Impact factor: 4.207

5.  S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine.

Authors:  Zhiyuan Zhou; Zhaoming Li; Zhenchang Sun; Xudong Zhang; Lisha Lu; Yingjun Wang; Mingzhi Zhang
Journal:  Sci Rep       Date:  2016-03-29       Impact factor: 4.379

6.  Reference intervals established using indirect method for serum ferritin assayed on Abbott Architect i2000SR analyzer in Chinese adults.

Authors:  Qing-Ping Wang; Lin-Ying Guo; Zhi-Yong Lu; Jian-Wen Gu
Journal:  J Clin Lab Anal       Date:  2019-11-01       Impact factor: 2.352

7.  Increased serum level of interleukin-6 correlates with negative prognostic factors in extranodal NK/T-cell lymphoma.

Authors:  Changqian Bao; Lixia Zhu; Wenbin Qian; Xiujin Ye
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.